A new generation of antibiotics can relieve chronic stomach pain and other symptoms of the condition.
They have helped treat millions of people around the world, but this new class of drugs can be more effective than the drugs currently on the market.
In a study published in Nature Medicine, scientists found a new class called herpes medicine.
The drugs can act in a similar way to drugs currently used for chemotherapy and are better tolerated.
But they are cheaper and they also work faster, making them ideal for people who suffer from stomach pain.
In the study, scientists used a strain of the herpes simplex virus that causes common colds, such as sore throats, to test for the drug and found it could be made from a different type of viral compound called a glycoprotein.
They also used a different version of the molecule to see if it could treat a different form of the disease, called refractory chronic constipation.
“It’s a novel class of therapies that could potentially have a huge impact in the treatment of chronic constipated gastroesophageal reflux disease,” says Dr. Richard Tannenbaum, an associate professor of medicine at Stanford University School of Medicine and co-author of the study.
The researchers used a new type of glycoproteins called glycopyranoside-1, a group of proteins that is found in many bacterial species.
They found that the molecule was present in many different species of bacteria and could be used to produce new drugs in a way that would not interfere with other therapies.
The findings could lead to a class of antibiotics that could be easily administered, with little side effects.
They can also be used by people with refractoric conditions who are not on antibiotics.
“This is a very exciting study that gives us a glimpse of how these new therapeutics could work in the stomach,” says John Wysocki, a professor of gastroenterology and hepatology at the University of California, San Francisco, who was not involved in the study but was part of a team that found the drug.
The study was funded by the National Institutes of Health.
The new class will likely be more expensive, but researchers hope it could help people in some cases, and it could provide a new avenue to develop new therapies for chronic constipt, which causes severe constipation that lasts for months or years.
People with refrractory constipation also can have a weakened immune system that can lead to serious infections and infections that cause serious illness.
The treatment can help patients with refrapped conditions recover more quickly and can help reduce the frequency of serious infections.
“There’s not a lot of research that looks at chronic constitutions or refractories, and we didn’t really have a good treatment,” says Tannengbaum.
“So now we have this new drug class that might be the next big thing in the field.”
The new drugs have not yet been tested in people with this condition.
The next step will be to test them in a group with refrained constipation and a refractorial condition.
Tannensbaum says it will take about three to four years for people with chronic constrictions to see benefit from the new drug.
“If we can find the right drug, it could very quickly go to clinical trials,” he says.
If successful, it would be a major step forward in the fight against the virus that infects about 2.3 million Americans.
This article was originally published on The Conversation.
Read the original article.
Follow LiveScience on Twitter @livescience.